DEC-C Trial for MDS Patients After Transplant
Phase 1/2
209
about 12 years
18–75
1 site in MO
What this study is about
This trial is testing if early treatment with DEC-C can help prevent relapse in people who have Myelodysplastic Syndromes (MDS) after a stem cell transplant. The goal is to see if detecting measurable residual disease and treating it with DEC-C improves outcomes.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take DEC-C
- 2.Use MyeloSeq-HD
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Maximum tolerated dose (MTD) (Phase I only), Progression-free survival (PFS) (Phase II recommended dose only)
Secondary: Overall survival (OS) (Phase II recommended dose only)